Everest Group (EG)
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-10-29
$410.97+2.59%
Close 2026-10-30 · 1-day change
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-10-29
Research Workspace
Put EG beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is contracting — down about 5% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 39%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskEG’s thesis rests on capital returns, but recent results show weakening business performance. Revenue declines eased from Q1 FY2026 to Q2 FY2026, before Q3 earnings missed. EG trades at 1× P/B versus peers’ 1.3×, and expectations look modest versus our view. The latest earnings miss raises concern, with our model placing next-quarter miss probability at 28%. Management is running behind on a stated commitment, the specific thesis risk. Peer multiples imply a price about 15% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. EG is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering EG (as of Oct 2026).
Based on 9 Wall Street analysts offering 12-month price targets for EG in the last 4 months.
Continue this research
Compare EG with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| EG Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financials (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put EG next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Accelerate capital return to shareholders
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $410.97
The last 12 months of price, then the range of analyst 12-month targets from today’s $410.97.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
A stated buyback floor supports capital returns; reserve strengthening signals underwriting caution.
Recall may impact brand reputation and sales.
Concerns over casualty reserves impact underwriting discipline.
Quiet hurricane season supports growth in specialty markets.
Shelf registration indicates commitment to capital return.
Expands product portfolio, aligning with growth objectives.
Strengthens presence in ophthalmology, supporting growth strategy.
Commercialization agreement enhances product offerings.